Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
Bill to pay for multi-cancer early detection screening test has bipartisan support, but just ran out of time last session.
On January 16, 2025, the Food and Drug Administration (FDA) issued an order banning FD&C Red No.3 in food and ingested drugs.1 Food and ingested ...
7d
In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...
The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback